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Tyrosine kinase activity s associated with the transforming potential of several oncogenes. Human chronic 
myeloid leukemia (CML) cells and cell lines have been shown to contain an active bcr-c-abl p210 tyrosine 
kinase as a consequence of the Philadelphia chromosomal translocation. In the present work the activity 
of the c-abl and c-src oncogene-encoded tyrosine kinases was investigated during phorbol diester (TPA) in- 
duced differentiation f the K562 CML cells. The high tyrosine kinase activity of p210 bcre'~ is strongly 
reduced uring the initial 24 h of TPA treatment. In contrast, he activity of the c-src tyrosine kinase is 
not changed. No change occurs in the expression of the c-abl-specific RNAs during this period. Following 
the reduction of bcr-c-abl kinase activity, cell proliferation is arrested and megakaryoblastic antigens appear 
on the cells. Sodium butyrate caused a slight decrease in growth rate and of bcr-c-abl kinase activity during 
erythroid ifferentiation whereas no changes in c-src or c-abl tyrosine kinase activities were seen in DMSO- 
treated control cells. 
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1. INTRODUCTION 
The K562 cells have several erythroid 
characteristics [1,2], but can be differentiated 
along either the megakaryoblastic or erythroid 
lineages [3-5]. Collins and Groudine found that 
the c-abl oncogene sequences in K562 cells are rear- 
ranged and amplified, and produce a novel 
transcript of about 8.5 kb [6-8]. This rearrange- 
ment of c-abl is typical for CML [8,9], and consists 
of a replacement of the 5' c-abl oncogene se- 
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quences with DNA from the brc gene of 
chromosome 22 due to a translocation of the c-abl 
DNA from chromosome 9 to the Philadelphia 
chromosome .[10,11]. The resulting bcr-c-abl fu- 
sion transcript encodes the p210 bcr'c-abt protein, 
which has an enhanced tyrosine kinase activity 
when compared with the corresponding normal 
protein P145 c-abt [11,12]. It has been proposed that 
the fusion protein, which resembles the oncogene- 
encoded protein of the Abelson murine leukemia 
virus, is responsible for increased cell proliferation 
during the chronic phase of CML [13]. However, 
hematopoietic cells of CML patients undergo near- 
ly normal differentiation until the blast crisis [14]. 
It is intriguing whether the maturation of CML 
cells can occur in the presence of the high bcr-c-abl 
oncoprotein tyrosine kinase activity. A model to 
study this question in vitro is provided by the 
megakaryoblastic and erythroid ifferentiation of 
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the K562 leukemia cells induced by TPA and 
sodium butyrate, respectively. 
We have previously shown that the c-abl mRNA 
levels do not change during megakaryoblastic dif- 
ferentiation of K562 cells [15]. Here I report the 
unexpected finding that the c-abl tyrosine kinase 
activity is strongly down-regulated early during 
TPA treatment and subsequent differentiation, 
when there is also an arrest of cell proliferation. 
2. MATERIALS AND METHODS 
2.1. Culture and treatment of the cells 
The K562 cells [1] were grown in RPMI 1640 
medium supplemented with 10°70 inactivated fetal 
calf serum and antibiotics. Differentiation was in- 
duced at a cell density of about 3 × 105/ml with 
TPA (1.6-3 nM, Sigma) dissolved in DMSO or 
with sodium butyrate (1.2 mM). Control cells were 
left untreated or treated with DMSO alone. 
2.2. Immunological reagents 
The anti-pEX-2 and anti-pEX-5 rabbit anti-abl- 
protein antibodies [11] were a kind gift from Dr 
Owen Witte and the Rous sarcoma virus-induced 
tumor-bearing rabbit serum (TBRS) from Dr Her- 
man Oppermann [16]. Monoclonal anti-src- 
protein antibodies 327 were a kind gift from Dr 
Joan Brugge [17] and the anti-phosphotyrosine an-
tibodies were from Dr H. Fujio (Osaka University, 
Japan) [181. 
2.3. Immunoprecipitation a d kinase assays 
2 x l0  7 cells were washed three times with PBS, 
suspended in 70 #1 PBS, and lysed rapidly in cold 
kinase lysis buffer (1°70 Triton X-100, 0.05°7o SDS, 
10 mM Na2HPOa-NaH2PO4, pH 7.0, 150 mM 
NaCI [9]). Subsequent immunoprecipitation a d 
kinase reactions were performed as described by 
Konopka and Witte [11,12]. For pp60 c-~rc kinase 
assays 20 mM MgCI2 was added to the reaction 
mixture. [7-32p]ATP (5-10#Ci/reaction, Amer- 
sham RPN 168), together with 0.8/zM unlabeled 
ATP was added to initiate the kinase reaction 
which was carried out at 30°C for 10-30 rain. 
Phosphorylated proteins were separated in 
polyacrylamide gel electrophoresis under reducing 
conditions. Some autoradiograms were quan- 
titated using densitometric scanning with 
Ultrascan (LKB, Bromma, Sweden). 
3. RESULTS 
K562 cells treated with nanomolar concentra- 
tions of TPA cease cell division within the first 
24 h as shown by cell counting (fig. 1A). A decrease 
in thymidine incorporation is seen within hours 
after the addition of TPA and by 4 days of treat- 
ment is only 7°7o of control (fig.lB). Flow 
cytometric analysis of cellular DNA content con- 
firms the virtual absence of cells in the S-phase of 
cell cycle 4 days after addition of TPA (fig.2). 
Sodium butyrate-treated ceils showed only modest- 
ly decreased growth (fig.l). At 2 and 4 days of 
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Fig. 1. Proliferation (A) and thymidine incorporation (B) 
of DMSO-, TPA- and butyrate-treated K562 cells. (A) 
Cell number/#l was counted after trypan blue vital 
staining. (B) At indicated times a 4 h pulse with 0.4 #Ci 
[3H]thymidine was given and 2 x 105 cells were 
harvested for measurement of acid-insoluble 
radioactivity. Thymidine incorporation is expressed as 
percentage of incorporation compared to cells treated 
with DMSO for the same time period. Shown are mean 
values calculated from three separate experiments. 
Variation between values was less than 10°70. 
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from TPA-treated ceils. There was only a slight 
reduction in the kinase activity in samples from 
sodium butyrate-treated cells in comparison with 
the control cells. The c-src kinase activity 
recovered from the same samples with TBRS, on 
the contrary, remains unaltered by either TPA or 
butyrate treatment (fig.3). A similar result was also 
obtained using anti-src monoclonal antibodies 327 
([171; not shown). 
Anti-phosphotyrosine immunocomplex kinase 
reactions were analyzed in parallel with the anti- 
pEX-5 abl-protein immunoprecipitates. The 
results in fig.4 show that antiphosphotyrosine an- 
Fig.2. Flow cytometric analysis of the DNA content of 
DMSO-treated (A) and TPA-treated (B) K562 cells. 
Cells treated for 4 days with TPA or DMSO were stained 
with ethidium bromide, and their DNA content was 
analyzed by FACS IV. Chick erythrocyte nuclease was 
used as a calibration standard (e). The percentage of 
cells in the S-phase in (A) is about 56%. In (B), twice the 
amount of cells shown in (A) were analyzed, to 
document the virtual absence (less than 20°/o) of cells in 
the S-phase. 
-~aN 
treatment, respectively, 5 and 10070 of nuclease 
from TPA-induced cells contain more than a 
diploid amount of DNA suggesting the develop- 
ment of nuclear polyploidy (not shown). As shown 
by others [3,4] and in our previous work [15] the 
TPA-induced K562 cells acquired several 
megakaryoblastic features. 
Anti-abl-protein immunocomplex kinase reac- 
tions from K562 cells treated for 4 days with TPA, 
sodium butyrate or as a control with DMSO were 
analysed by polyacrylamide gel electrophoresis. 
The p210 ~r'c-abt along with several other polypep- 
tides were phosphorylated in samples from 
DMSO-treated control cells. In contrast, no 
phosphoproteins were seen in reaction mixtures 
Fig.3. Comparison of the c-src and bcr-c-abl kinase 
activities in differentiating K562 cells. Immunocomplex 
kinase assays were performed as described in section 2.3 
using anti-pEX-5 antiserum or TBRS respectively, from 
cells differentiated for 4 days. Samples were separated in
10% polyacrylamide gel and stained with Coomassie 
brilliant blue (CBB) and subjected to autoradiography. 
Shown is an 8 h autoradiogram and the stained gel, with 
molecular mass markers indicated on the left. The 
positions of the IgG heavy (IgH, 50 kDa) and light (IgL, 
25 kDa) chains are indicated on the right. The film was 
overexposed to document the virtual absence of 
phosphoproteins in the TPA lane. The major 
phosphopolypeptides s en in the pEX-5 lanes are better 
visualized in fig.4. The slight amount of the 210 kDa 
polypeptide among the TBRS phosphoproteins from 
TPA-treated ceils represents sample leakage from the 
adjacent pEX-5 lane of butyrate-treated cells. 
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Fig.4. Comparison of kinase activities immuno- 
precipitated from K562 cells with anti-phosphotyrosine 
(P-tyr) or with the pEX-5 antibodies. Cells treated with 
DMSO or TPA for 24 h were immunoprecipitated with 
the two antisera and analyzed by the kinase assay 
followed by electrophoresis in a 7.5070 gel. In longer 
exposure lower molecular mass polypeptides were seen 
in the pEX-5 (DMSO) lane. 
tibodies yield a phosphopolypeptide comigrating 
with the 210 kDa bcr-¢-abt phosphoprotein. In addi- 
tion, they yield a polypeptide of 190 kDa (a 
probable degradation product of p210 [19]) and 
minor phosphopolypeptides of 90 and 41 kDa ap- 
parent molecular masses. This analysis shows that 
a major tyrosine-phosphorylated protein in un- 
treated K562 cells is the abi oncogene-encoded 
tyrosine kinase, and that the activity of the kinase 
declines during differentiation as measured by two 
independent antibodies. 
The bcr-c-abl kinase activity was decreased 
already 1.5 h after TPA induction and even more 
at 4.5 h (fig.5). There were practically no proteins 
phosphorylated in the immunocomplex kinase 
reaction from cells differentiated for 24 h. 
Fig.5. Kinetics of the c-abl kinase downregulation 
during TPA-lnduced differentiation. Immunocomplex 
kinase assays were performed using K562 cells treated 
with TPA for the indicated lengths of time. The proteins 
were analyzed by electrophoresis and autoradiography 
as in fig.3. The electrophoretic mobilities of the 
p210 ~r-c-abt fusion protein and the 56 and 47 kDa major 
phosphoproteins are shown. The vague bands een in the 
24 h lane represent leakage of molecular mass markers 
from the adjacent lane. (C) Control experiment with 
untreated cells. Other symbols as in fig.3. 
Several other phosphoproteins are seen in the 
bcr-c-abl kinase reactions. The most prominent 
polypeptides, of 56 and 47 kDa are marked in 
fig.5. The identities of these phosphoproteins are 
not known. Alkaline treatment of the gels, which 
has been shown to enrich in phosphotyrosine at the 
cost of phosphoserine and phosphothreonine [20] 
resulted in about 50% reduction in the intensity of 
the radioactive signal from the 56 kDa polypeptide 
band as well as from the minor 50 kDa polypeptide 
when measured by densitometric s anning. In con- 
trast, the degree of phosphorylation of the 210, 
190 and 47 kDa polypeptides were not altered. 
Thus, the 56 and 50 kDa phosphoprotein species 
probably contain a major portion of their 
phosphate in phosphoserine and phospho- 
threonine. This was also suggested by their absence 
from the anti-phosphotyrosine immunopreci- 
pitates. 
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4. DISCUSSION 
Our previous investigations  growth factor 
and oncogene RNA expression i K562 cells how- 
ed that the bcr-c-abl oncogene RNA persists in 
K562 cells despite their differentiation and de- 
creased proliferation [15]. Since it was unexpected 
to find oncogene RNA expression being maintain- 
ed in differentiating cells, we decided to study the 
activity of the protein product of the bcr-c-abl 
tyrosine kinase. The present results document the 
virtual absence of tyrosine kinase activity in TPA- 
treated K562 cells as measured by the im- 
munocomplex kinase assay using two different an- 
tisera. We also made a comparison with sodium 
butyrate-treated K562 cells, which show erythroid 
differentiation. Only a slight reduction of the 
kinase activity occurs in these cells. 
The immunoprecipitation and immunocomplex 
kinase experiments with anti-phosphotyrosine a - 
tibodies suggest that a major portion of 
phosphotyrosine i  K562 cell polypeptides resides 
in the bcr-c-abl kinase. Similar amounts of kinase 
activity were precipitated with both anti-abl and 
anti-phosphotyrosine antibodies, although the 
sizes of polypeptides precipitated w re somewhat 
different, probably due to different degrees of pro- 
teolytic degradation (see e.g. [19]). The mechanism 
for the observed ifference in the kinase activities 
of TPA-treated and control cells is unknown. Our 
immunoprecipitation experiments are too insen- 
sitive to detect metabolically labelled bcr-c-abl pro- 
tein in K562 cells. Therefore, we are as yet 
uncertain, whether there is ~ reduction in the 
amount of the protein, its kinase activity or in the 
activities of possible phosphatases in the im- 
munocomplexes. Several other phosphopolypep- 
tides are found in the pEX-5 immunocomplex 
kinase reactions, when analyzed bypolyacrylamide 
gel electrophoresis. The major phosphopolypep- 
tides of 56 and 50 kDa probably contain most of 
their radioactive label 
phosphothreonine. These 
spond to these reported 
Concomitant with the 
tyrosine kinase-catalyzed 
in phosphoserine and 
polypeptides may corre- 
by Maxwell et al. [21]. 
disappearance of the 
phosphorylations, there 
seems to be a reduction in serine and threonine 
phosphorylations, possibly by c-abl-independent, 
contaminating kinases. However, the intensity of 
these polypeptides varied in different experiments 
and they were not seen in kinase-labeled anti- 
phosphotyrosine immunoprecipitates. 
The c-src kinase activity was not detectably af- 
fected by TPA treatment. This is particularly in- 
teresting, since high levels of the c-src kinase and 
phosphotyrosine are found in platelets [22]. 
The abnormal bcr-c-abl tyrosine kinase activity 
could cause the proliferative advantage of CML 
cells, such as the cell line K562. It is shown here 
that during induction of megakaryoblastic dif- 
ferentiation ofK562 cells with the protein kinase C 
activator TPA [23] this tyrosine kinase activity is 
strongly downregulated and simultaneously the 
cells stop dividing. Further studies are required to 
clarify whether and how these events are inter- 
related. 
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